These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3806082)

  • 1. Iron, a new aid in the treatment of Parkinson patients.
    Birkmayer W; Birkmayer JG
    J Neural Transm; 1986; 67(3-4):287-92. PubMed ID: 3806082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of disability and akinesia of patients with Parkinson's disease by intravenous iron substitution.
    Birkmayer JG; Birkmayer W
    Ann Clin Lab Sci; 1987; 17(1):32-5. PubMed ID: 3579206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy].
    Fuchs G
    Fortschr Med; 1997 Feb; 115(5):43-5. PubMed ID: 9162718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
    Ghika J; Gachoud JP; Gasser U
    Clin Neuropharmacol; 1997 Apr; 20(2):130-9. PubMed ID: 9099465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?].
    Wedekind S
    MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 10. [L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism].
    Arai H; Shinotoh H; Hattori T
    Rinsho Shinkeigaku; 1997 Mar; 37(3):264-5. PubMed ID: 9217430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medical treatment of L-dopa induced dyskinesia].
    Kuno S
    Nihon Rinsho; 2000 Oct; 58(10):2110-4. PubMed ID: 11068456
    [No Abstract]   [Full Text] [Related]  

  • 12. [Parkinson therapy 1985].
    Kaeser HE
    Schweiz Med Wochenschr; 1986 Jun; 116(24):801-4. PubMed ID: 3726512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of pergolide in Parkinson's disease].
    Gonce M; Delwaide PJ
    Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-duration response to L-dopa in the treatment of early PD.
    Zappia M; Oliveri RL; Bosco D; Nicoletti G; Branca D; Caracciolo M; Napoli ID; Gambardella A; Quattrone A
    Neurology; 2000 May; 54(10):1910-5. PubMed ID: 10822428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Tomiyama M; Kimura T; Maeda T; Kannari K; Matsunaga M; Baba M
    Neurosci Res; 2005 Jun; 52(2):185-94. PubMed ID: 15893579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
    Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacologic treatment of Parkinson disease].
    Murata M
    Brain Nerve; 2009 Apr; 61(4):464-72. PubMed ID: 19378816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.